Andrew has experience working on a full range of contentious and non-contentious intellectual property matters, with a strong focus on patent litigation and regulatory issues (including supplemental protection certificates) in the life sciences sector. Andrew has acted for clients in a broad spectrum of industries, including pharmaceutical products (for human and veterinary use, including medical devices), cosmetic products, TMT, manufacturing (e.g. can making) and has represented clients in disputes before the English Courts (Patents Court and Court of Appeal), the European Patent Office and the Court of Justice of the European Union.
Andrew also advises on licensing and contractual agreements relating to the development and exploitation of intellectual property rights.
- Recent Work
- representing Eli Lilly in a patent revocation action relating to therapeutic antibodies for treating Alzheimer’s disease, successfully revoking the patent at first instance
- representing GSK Vaccines in the prosecution of its SPC applications relating to adjuvanted influenza vaccines, in which questions have been referred to the CJEU in relation to the interpretation of the SPC Regulation
- representing Bayer in a patent revocation action relating to VEGF antagonists (including antibodies) used to treat non-neoplastic proliferative diseases, including ARMD
- representing Eli Lilly in a revocation action brought by Neopharma and Neolab concerning Eli Lilly’s olanzapine patent, obtaining a partial summary judgment and security for costs
- advising pharmaceutical companies on a range of contentious matters, including coordinating pan-European revocation and non-infringement proceedings
- advising pharmaceutical and biotech companies on regulatory issues relating to marketing authorizations and SPCs, including in relation to medical devices.
Andrew joined Simmons & Simmons in November 2010 having trained and qualified at the London offices of another global law firm. Andrew has experience working as part of an international team and has handled matters for clients involving the coordination of efforts and resources across US and European jurisdictions.
Before attending law school, Andrew studied Natural Sciences at Cambridge, where he specialised in Biochemistry and undertook a research project studying the role of amphiphysin in the development of mammalian skeletal muscle tissue (obtaining a fourth year MSci in 2002).
Andrew obtained his Diploma in Intellectual Property Law & Practice at Bristol University in 2007-2008 and he regularly writes articles and updates on intellectual property law.